Ownership and insider activity for Precigen, Inc. (PGEN): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies.
Price
| Price | $7.43 |
| Market Cap | $2.7B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-26 | KINDLER JEFFREY B | S-Sale | 185,000 | $1.4M |
| 2026-08-21 | AGEE NANCY H | P-Purchase | 3,411 | $25K |
| 2026-08-23 | Lehr Donald P. | M-Exempt | 5,208 | |
| 2026-08-23 | Lehr Donald P. | F-InKind | 2,488 | $18K |
| 2026-08-23 | Lehr Donald P. | M-Exempt | 5,208 | |
| 2026-08-23 | Thomasian Harry Jr. | M-Exempt | 7,291 | |
| 2026-08-23 | Thomasian Harry Jr. | F-InKind | 3,577 | $26K |
| 2026-08-23 | Thomasian Harry Jr. | M-Exempt | 7,291 | |
| 2026-08-21 | Shah Rutul R | M-Exempt | 34,658 | $81K |
| 2026-08-25 | Shah Rutul R | M-Exempt | 15,342 | $36K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $62.6M | $68.1M | $102.8M | $65.8M | $51.8M | $36.4M | $4.9M | $7.6M | $29.5M | $30.2M |
| Short-term Investments | $174.6M | $11.6M | $120.1M | $9.3M | $48.3M | $72.2M | $51.1M | $55.3M | $68.4M | $67.6M |
| Receivables | $42.5M | $39.8M | $26.6M | $26.2M | $20.4M | $2.0M | $13.8M | $1.6M | $1.2M | $4.4M |
| Inventory | $21.1M | $20.5M | $21.4M | $16.1M | $11.4M | $326000 | $287000 | 0 | 0 | $9.6M |
| Total Current Assets | $315.2M | $154.0M | $285.5M | $234.6M | $148.9M | $156.6M | $118.2M | $68.8M | $102.4M | $115.2M |
| Property, Plant & Equipment | $64.7M | $112.7M | $128.9M | $86.2M | $44.3M | $18.6M | $15.3M | $14.1M | $18.8M | $18.4M |
| Goodwill | $157.2M | $153.3M | $149.6M | $63.8M | $54.4M | $37.6M | $36.9M | $26.6M | $19.1M | $15.2M |
| Intangible Assets | $225.6M | $232.9M | $129.3M | $68.3M | $65.4M | $52.3M | $44.5M | $40.7M | $4.5M | $3.2M |
| Total Assets | $949.1M | $846.9M | $716.2M | $455.8M | $314.6M | $359.9M | $216.0M | $151.0M | $145.3M | $156.6M |
| Accounts Payable | $8.5M | $8.7M | $12.0M | $5.5M | $4.6M | $3.1M | $4.1M | $1.7M | $3.5M | $12.0M |
| Short-term Debt | $1.2M | $735000 | $945000 | $33.6M | $360000 | $52000 | $43.2M | 0 | 0 | 0 |
| Total Current Liabilities | $94.6M | $80.2M | $61.6M | $122.9M | $42.1M | $34.6M | $78.6M | $23.0M | $21.5M | $37.3M |
| Long-term Debt | $7.6M | $7.5M | $211.2M | $186.3M | $171.5M | $179.9M | 0 | 0 | 0 | $93.2M |
| Total Liabilities | $379.8M | $300.3M | $337.5M | $384.1M | $247.4M | $252.5M | $89.7M | $32.5M | $106.8M | $135.7M |
| Retained Earnings | -$729.3M | -$847.8M | -$1.33B | -$1.65B | -$1.82B | -$1.92B | -$1.87B | -$1.96B | -$2.09B | -$2.34B |
| Total Equity | $560.2M | $533.6M | $362.9M | $71.7M | $67.2M | $107.3M | $126.3M | $118.5M | $38.5M | $20.9M |
| Total Debt | $8.8M | $8.3M | $212.3M | $232.7M | $182.3M | $190.1M | $51.4M | $7.1M | $5.5M | $98.3M |
| Net Debt | -$228.4M | -$71.4M | -$10.6M | $157.6M | $82.2M | $81.4M | -$4.5M | -$55.8M | -$92.4M | $432000 |
| Working Capital | $220.6M | $73.9M | $223.9M | $111.7M | $106.8M | $122.0M | $39.5M | $45.8M | $80.9M | $77.9M |
Related companies: AMLX · DNTH · ELVN · IMTX · NKTR · ORIC · RLAY
Explore sector: Healthcare · Biotechnology
More sections of PGEN: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks